The Hindu : Business : Ranbaxy, GlaxoSmithKline reach settlement

Online edition of India's National Newspaper
Tuesday, Jan 22, 2008
ePaper | Mobile/PDA Version

Business

Business

Ranbaxy, GlaxoSmithKline reach settlement

MUMBAI: Pharmaceutical major Ranbaxy Laboratories on Monday said it has settled all matters relating to possible patent litigation with GlaxoSmithKline regarding the Sumatriptan Succinate Tablets, used for treating migraine.

Sumatriptan Succinate tablets are the generic version of GlaxoSmithKline’s Imitrex Tablets.

The terms of the settlement provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate tablets in multiple strengths of 25 mg, 50 mg and 100 mg in the U.S., Ranbaxy informed the Bombay Stock Exchange.

However, it did not disclose the additional terms of the settlement agreement.

The expected launch date is by December this year, the company added. — PTI

DRL, Novartis settle dispute

Our Hyderabad Correspondent writes:

Dr. Reddy’s Laboratories on Monday announced that it had entered into a settlement agreement with Novartis Pharma AG which involved a stipulation of dismissal of the lawsuits in the U.S. relating to the Abbreviated New Drug Applications (ANDA) filed by DRL for a generic version of Rivastigmine Tartrate capsules sold under the trade-name Exelon.

Under the terms of the agreement, DRL would not launch its generic Rivastigmine Tartrate capsules until sometime before the expiry of the Orange Book patents claiming Rivastigmine, according to a release.

The exact date of launch and other terms of this agreement were confidential, the release added.

Printer friendly page
Send this article to Friends by E-Mail

Business